How many drugs treat Candidal vulvovaginitis?

Drug Landscape tracks 7 marketed treatments for Candidal vulvovaginitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/candidal-vulvovaginitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Candidal vulvovaginitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Candidal vulvovaginitis (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Candidal vulvovaginitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Femstat 3	BUTOCONAZOLE	Bayer	Azole Antifungal		1995-01-01
Diflucan	fluconazole	Pfizer Inc.	Azole Antifungal [EPC]	Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase	1990-01-29
Lotrimin	clotrimazole	Bayer AG	Azole Antifungal [EPC]	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6	1975-01-01
Monistat	miconazole	Johnson & Johnson (Janssen)	Imidazole antifungal	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6	1974-01-01
Avc	SULFANILAMIDE	Pharmobedient	sulfanilamide	Carbonic anhydrase 13	1965-01-01
Mycostatin	nystatin	Generic (originally Squibb)	Polyene Antifungal [EPC]	Ergosterol (fungal cell membrane)	1954-01-01
Fluconazol	Fluconazol	Azienda Sanitaria-Universitaria Integrata di Udine		Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Candidal vulvovaginitis
Azienda Sanitaria-Universitaria Integrata di Udine · 1 drug in Candidal vulvovaginitis
Bayer · 1 drug in Candidal vulvovaginitis
Bayer AG · 1 drug in Candidal vulvovaginitis
Generic (originally Squibb) · 1 drug in Candidal vulvovaginitis
Johnson & Johnson (Janssen) · 1 drug in Candidal vulvovaginitis
Pfizer Inc. · 1 drug in Candidal vulvovaginitis
Pharmobedient · 1 drug in Candidal vulvovaginitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Candidal vulvovaginitis:

Cite this brief

Drug Landscape (2026). Candidal vulvovaginitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/candidal-vulvovaginitis. Accessed 2026-06-10.

Candidal vulvovaginitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing